Page 101 - Read Online

Sell et al. Mini-invasive Surg 2024;8:3 https://dx.doi.org/10.20517/2574-1225.2023.105 Page 9 of 10

high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80. PubMed
39. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated
radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38:280-7. PubMed
40. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck
squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9. DOI PubMed
18
41. Workman AD, Glicksman JT, Parasher AK, et al. FDG PET/CT in routine surveillance of asymptomatic patients following treatment
of sinonasal neoplasms. Otolaryngol Head Neck Surg 2017;157:1068-74. DOI PubMed
42. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the
follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22.
DOI PubMed
43. Keski-Säntti H, Mustonen T, Schildt J, Saarilahti K, Mäkitie AA. FDG-PET/CT in the assessment of treatment response after
oncologic treatment of head and neck squamous cell carcinoma. Clin Med Insights Ear Nose Throat 2014;7:25-9. DOI PubMed PMC
44. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck
cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083-95. DOI PubMed
45. Gil Z, Even-Sapir E, Margalit N, Fliss DM. Integrated PET/CT system for staging and surveillance of skull base tumors. Head Neck
2007;29:537-45. DOI PubMed
46. Abu-Ghanem S, Yafit D, Ghanayem M, Abergel A, Yehuda M, Fliss DM. Utility of first positron emission tomography-computed
tomography scan as a prognostic tool following treatment of sinonasal and skull base malignancies. Head Neck 2019;41:701-6. DOI
PubMed
18
47. Ozturk K, Gencturk M, Caicedo-Granados E, Li F, Cayci Z. Performance of whole-body F-FDG PET/CT as a posttreatment
surveillance tool for sinonasal malignancies. Eur Arch Otorhinolaryngol 2019;276:847-55. DOI PubMed
48. Akay S, Pollard JH, Saad Eddin A, et al. PET/CT imaging in treatment planning and surveillance of sinonasal neoplasms. Cancers
2023;15:3759. DOI PubMed PMC
49. Patel TD, Vazquez A, Dubal PM, Baredes S, Liu JK, Eloy JA. Sinonasal neuroendocrine carcinoma: a population-based analysis of
incidence and survival. Int Forum Allergy Rhinol 2015;5:448-53. DOI PubMed
50. van der Laan TP, Iepsma R, Witjes MJH, van der Laan BFAM, Plaat BEC, Halmos GB. Meta-analysis of 701 published cases of
sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol 2016;63:1-9.
DOI PubMed
68
51. Liu KY, Goldrich DY, Ninan SJ, et al. The value of Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management:
a case series. Head Neck 2021;43:E30-40. DOI PubMed
52. Roytman M, Tassler AB, Kacker A, et al. [68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of
esthesioneuroblastoma: illustrative cases. J Neurosurg Case Lessons 2021;1:CASE2058. DOI PubMed PMC
53. Amit M, Tam S, Abdelmeguid AS, et al. Patterns of treatment failure in patients with sinonasal mucosal melanoma. Ann Surg Oncol
2018;25:1723-9. DOI
54. Tzelnick S, Levin EG, Yacobi D, Mizrachi A, Popovtzer A, Soudry E. Recurrence patterns and efficacy of surveillance modalities for
sinonasal malignancies. Am J Rhinol Allergy 2022;36:473-9. DOI PubMed
55. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013;121:4997-5005. DOI
56. Wong KF, Chan JKC, Cheung MMC, So JCC. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J
Clin Pathol 2001;115:266-70. DOI PubMed
57. Wang Y, Xie L, Tian R, et al. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in
part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. J Cancer Res Clin Oncol 2019;145:2529-39. DOI
58. Nowak B, Di Martino E, Jänicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to
CT/MRI. Nuklearmedizin 1999;38:312-8. DOI
59. Ramsay HA, Kairemo KJA, Jekunen AP. Somatostatin receptor imaging of olfactory neuroblastoma. J Laryngol Otol 1996;110:1161-3.
DOI PubMed
60. Bishop JA, Ogawa T, Stelow EB, et al. Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant
of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol 2013;37:836-44. DOI PubMed PMC
61. Zupancic M, Näsman A. Human papillomavirus-related multiphenotypic sinonasal carcinoma-an even broader tumor entity? Viruses
2021;13:1861. DOI PubMed PMC
62. Chang Sing Pang KJW, Mur T, Collins L, Rao SR, Faden DL. Human papillomavirus in sinonasal squamous cell carcinoma: a
systematic review and meta-analysis. Cancers 2020;13:45. DOI PubMed PMC
63. Naegele S, Efthymiou V, Das D, et al. Detection and monitoring of circulating tumor HPV DNA in HPV-associated sinonasal and
nasopharyngeal cancers. JAMA Otolaryngol Head Neck Surg 2023;149:179-81. DOI PubMed PMC
64. Huang SH, Jacinto JCK, O’Sullivan B, et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal
carcinoma in a North American cohort. Cancer 2022;128:2908-21. DOI PubMed
65. Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of
American Pathologists. Arch Pathol Lab Med 2018;142:559-97. DOI
66. Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a
multicentre, retrospective analysis. Lancet Oncol 2016;17:389-400. DOI